ABSTRACT
OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated. PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire. RESULTS: DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itch-VAS (p=0.16). CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
Subject(s)
COVID-19 , Chilblains , Dermatitis , Psoriasis , Skin Diseases , Humans , Child , Chilblains/diagnosis , Case-Control Studies , Psoriasis/diagnosis , Parents , Toes , Severity of Illness IndexSubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Psoriasis/drug therapy , Thalidomide/analogs & derivatives , Administration, Oral , Adult , Aged , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/virology , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/therapeutic use , Female , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Phosphodiesterase 4 Inhibitors/administration & dosage , Phosphodiesterase 4 Inhibitors/therapeutic use , Psoriasis/pathology , SARS-CoV-2/genetics , Symptom Flare Up , Thalidomide/administration & dosage , Thalidomide/therapeutic useSubject(s)
COVID-19 Vaccines/administration & dosage , Health Personnel , Immunosuppressive Agents/therapeutic use , Psoriasis/drug therapy , Adult , Aged , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , BNT162 Vaccine , COVID-19 Vaccines/adverse effects , Female , Humans , Immunosuppressive Agents/adverse effects , Italy , Male , Middle Aged , SARS-CoV-2Subject(s)
Betacoronavirus/immunology , Biological Products/adverse effects , Coronavirus Infections/epidemiology , Hospitalization/statistics & numerical data , Pneumonia, Viral/epidemiology , Psoriasis/drug therapy , Adult , Aged , Betacoronavirus/isolation & purification , COVID-19 , Comorbidity , Coronavirus Infections/immunology , Coronavirus Infections/virology , Female , Hospital Mortality , Humans , Italy/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , Psoriasis/epidemiology , Psoriasis/immunology , Retrospective Studies , SARS-CoV-2ABSTRACT
SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics—51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P =.001) with higher scholarity level (P =.005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P =.006), longer disease duration (P =.051) and lower scholarity (P =.007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption.